Announcements Trials
Browse Landscape

Phase

Phase 2 133Phase 3 32Phase 1/2 30Phase NA 15Phase 1 10Phase 4 6Phase 2/3 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Genitourinary 1Dermatologic 1

Conditions

Neoplasms 18Prostatic Neoplasms 16Breast Neoplasms 11Recurrence 8Leukemia, Myeloid, Acute 8Neoplasm Metastasis 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Colorectal Neoplasms 6Ovarian Neoplasms 5Myelodysplastic Syndromes 5Multiple Myeloma 5Melanoma 5Leukemia 5Head and Neck Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Lymphoma, Non-Hodgkin 4Lung Neoplasms 4Fatigue 4Vomiting 3Stomach Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Prostatic Neoplasms, Castration-Resistant 3Pain 3Oropharyngeal Neoplasms 3Nausea 3Mesothelioma 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma 3Liposarcoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3

Interventions

Interferon alpha-2 2peginterferon alfa-2b 1peginterferon alfa-2a 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Has results × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × Clear all
NCT03547154 2019-08-12

C98026

Merck Sharp & Dohme LLC

Phase 2/3 Terminated
344 enrolled 11 charts
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02829775 2017-01-09

A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies

Hoffmann-La Roche

Phase 2/3 Completed
9 enrolled 7 charts
DermatologicGenitourinaryMyeloidOther hematologic neoplasm

Carcinoma, Renal Cell, Melanoma, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡